Devils Lake, N.D. – The Blue Cross Blue Shield of North Dakota (BCBSND) Caring Foundation and Altru Health Foundation ...

Humacyte (HUMA) just shared new two-year results from its V007 Phase 3 study at Kidney Week 2025. The ATEV device performed better than traditional AV fistulas for hemodialysis access, particularly in ...

Vexev, announced the highly successful results of the CANSCAN Trial (NCT06691672), providing evidence that the VxWave ...

The VxWave system’s potential ability to standardize examinations would allow dialysis clinics to better determine subgroups who may be at a disadvantage for vascular access creation, ultimately ...

Vexev and U.S. Renal Care today announced successful results from the CANSCAN trial of the VxWave robotic ultrasound imaging system.

Humacyte (HUMA) announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered ...

The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The ...

The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional ...

The local renal unit is set to receive a new machine that monitors fistulas in dialysis patients, thanks to years of ...

The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional dialysis program piloted ...

The cost of emergency dialysis is estimated to be eight times that of in-center dialysis. A new study reveals that a ...